CONDITIONAL RESOLUTIONS IN THE AMNOG EARLY BENEFIT ASSESSMENT

被引：0
|
作者：
Assmann, G. [1 ]
Schmidt, U. [1 ]
Drechsler, M. [1 ]
Pfannkuche, M. [1 ]
机构：
[1] Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany
来源：
VALUE IN HEALTH | 2014年 / 17卷 / 07期
关键词：
D O I：
10.1016/j.jval.2014.08.1161
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PHP225
引用
收藏
页码：A442 / A442
页数：1
相关论文
共 50 条
  • [31] INTRODUCTION TO THE AMNOG BENEFIT ASSESSMENT IN GERMANY AND ANALYSIS OF ITS OUTCOMES FROM 2011 TO 2019
    Feindt, W.
    Sauer, A. K.
    Eckert, N.
    Loepmeier, J. F.
    Kulp, W.
    VALUE IN HEALTH, 2020, 23 : S659 - S659
  • [32] REPURPOSED DRUGS LAUNCHED UNDER THE AMNOG IN GERMANY: EFFECTS ON BENEFIT ASSESSMENT AND PRICE DEVELOPMENT
    Sake, S. M.
    Martyniszyn-Eiben, A.
    Zavatta, E.
    Gluesen, M.
    Berger, I
    Schoenermark, M.
    VALUE IN HEALTH, 2022, 25 (12) : S261 - S261
  • [33] 2.5 YEARS OF AMNOG IN GERMANY - AN ANALYSIS OF BENEFIT ASSESSMENT AND NET PRICE NEGOTIATION TRENDS
    Dehnen, J.
    Schmoeller, M.
    VALUE IN HEALTH, 2013, 16 (07) : A456 - A457
  • [34] SURROGATE VALIDATION IN GERMAN AMNOG BENEFIT ASSESSMENTS
    Gingrich, A.
    Baigger, A.
    Scharrenbroich, J.
    Erwes, K. L.
    Kulp, W.
    Templin, C.
    VALUE IN HEALTH, 2019, 22 : S795 - S795
  • [35] Benefit Assessment and Price Negotiation Under AMNOG: Calculable Process or Unfair Poker Game?
    Radic, D.
    Haugk, S.
    Radic, M.
    GESUNDHEITSWESEN, 2018, 80 (06) : 573 - 579
  • [36] EXTRAPOLATION OF ADULT DATA FOR PEDIATRIC DRUG BENEFIT ASSESSMENT IN THE AMNOG DOSSIER IN THE LIGHT OF THE NEW AMVSG
    Stoecker, P.
    Bonduelle, D.
    Hofmann-Xu, L.
    VALUE IN HEALTH, 2017, 20 (09) : A698 - A698
  • [37] IMPORTANCE OF HEALTH-RELATED QUALITY OF LIFE AS AN ENDPOINT IN BENEFIT ASSESSMENT ACCORDING TO THE GERMAN AMNOG
    Koester, C.
    Kossmann, B.
    Boehm, K.
    Wasem, J.
    Aidelsburger, P.
    VALUE IN HEALTH, 2012, 15 (07) : A310 - A310
  • [38] Early Benefit Assessment Importance of scientific Expert Association in the early Benefit Assessment of Pharmaceuticals
    Potempa, Christoph
    GESUNDHEITSOEKONOMIE UND QUALITAETSMANAGEMENT, 2018, 23 (04): : 179 - 179
  • [39] Drug Assessment Post AMNOG - Limits to Benefit Assessment by Separating Health and Long Term Care Insurance: The Example of Dementia
    Ulrich, V.
    Maier, C.
    GESUNDHEITSOEKONOMIE UND QUALITAETSMANAGEMENT, 2015, 20 (02): : 68 - 78
  • [40] 10 YEARS OF AMNOG: IMPORTANCE OF REAL-WORLD EVIDENCE STUDIES IN THE GERMAN BENEFIT ASSESSMENT PROCESS
    Seidel, K.
    Schnaidt, S.
    Viering, T.
    Loepmeier, J. F.
    Borchert, K.
    Jacob, C.
    VALUE IN HEALTH, 2022, 25 (12) : S314 - S314
12345